Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6294

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors

Merck (avelumab)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Action Kidney Cancer

 

Kidney Cancer UK

 

Kidney Research UK

Professional groups

Association of Cancer Physicians

 

British Uro-oncology Group

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Associated public health groups

None

Comparator companies

Bristol Myers Squibb Pharmaceuticals (ipilimumab, nivolumab) (confidentiality agreement signed, participating)

 

Eisai (lenvatinib) (confidentiality agreement signed, participating)

 

Ipsen (cabozantinib) (confidentiality agreement signed, participating)

 

Merck Sharp & Dohme (UK) (pembrolizumab) (confidentiality agreement signed, participating)

 

Pfizer (sunitinib) (confidentiality agreement signed, participating)

 

Accord-UK (sunitinib) (confidentiality agreement not signed, not participating)

 

Dr Reddy’s Laboratories (sunitinib) (confidentiality agreement not signed, not participating)

 

Eusa Pharma (tivozanib) (confidentiality agreement not signed, not participating)

 

MSN laboratories (sunitinib) (confidentiality agreement not signed, not participating)

 

Novartis (pazopanib) (confidentiality agreement not signed, not participating)

 

Piramal Critical Care (sunitinib) (confidentiality agreement not signed, not participating)

 

Sandoz (sunitinib) (confidentiality agreement not signed, not participating)

 

Teva UK (sunitinib) (confidentiality agreement not signed, not participating)

 

Viatris UK Healthcare (sunitinib) (confidentiality agreement not signed, not participating)

 

Zentiva (sunitinib) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health, Social Services and Public Safety for Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual